ITGAM and neoplasm: Additional phenotyping of macrophages (CD45high/CD11b+ population) showed that CDNP-R848 treatment leads to a pro-inflammatory shift of TAMs with the enhanced presence of pro-inflammatory F4/80+/MHCII+ macrophages during the effector and tumor clearing phases (Fig. 5b, e).